Comparison_of_02_and_018_hyaluronate_eye_drops_in_patients_with_moderate_to_severe_dry_eye_with_keratitis_or_keratoconjunctivitis-1.jpg

Compare efficacy and safety of 0.2% and 0.18% hyaluronic acid (HA) eye drops three times a day (tid) in patients with moderate to severe dry eye disease, related to keratitis or keratoconjunctivitis

Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis

Article specifications

This Prospective, multicenter, randomized, single-masked, phase IIIb, noninferiority study was published in 2017 in Journal of Clinical Ophthalmology (IF2017: 0.84) by French and German ophthalmologists. The aim of this study was to Compare efficacy and safety of 0.2% and 0.18% hyaluronic acid (HA) eye drops three times a day (tid) in patients with moderate to severe dry eye disease, related to keratitis or keratoconjunctivitis. Thirty-eight patients were included in the 0.18% HA group, and 32 in the 0.2% HA group.

 

Results

0.2% and 0.18% HA eye drops significantly improved signs and symptoms of dry eye disease and were well tolerated with few AEs. Noninferiority of 0.2% HA compared to 0.18% HA was demonstrated for reduction of OS lesions. In some parameters, there was a nonsignificant trend in favor of 0.2% HA concentration.

Tags: Germany France Clinical trial 2017 Clin Ophthalmol

Hayland Center

© 2018 HYLAND.CENTER ALL RIGHTS RESERVED